[1] Bunikowski R, Staab D, Kussebi F, et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis:clinical and immunological effects. Pediatr Allergy Immunol, 2001,12:216-223.
[2] Brazzelli V, Prestinari F, Chiesa MG, et al.Sequential treatment of severe atopic dermatitis with cyclosporin A and low-dose narrow-band UVB phototherapy. Dermatology, 2002,204:252-254.
[3] Grundmann-Kollmann M, Podda M,Oehsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol, 2001,137:870-873.
[4] Benez A, Fierlbeck G. Successful longterm treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol, 2001,144:638-639.
[5] Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol, 2000,42:1033-1040.
[6] Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy, 1998,53:1202-1207.
[7] Huang JL, Lee WY, Chen LC, et al. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol,2000,84:345-352.
[8] Noh G, Lozano F. Intravenous immune globulin effects on serum-soluble CD5 levels in atopic dermatitis. Clin Exp Allergy,2001,31:1932-1938.
[9] Carucci JA, Washenik K, Weinstein A, et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol, 1998,134:785-786.
[10] Woodmansee DP, Simon RA.A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol,1999,83:548-552.
[11] Back, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Dermatol Venereol, 2001,15:34-38.
[12] Robinet E, Stamm C, Nicolas JF, et al. CD4 monoclonal antibody administration in atopic dermatitis. J Am Acad Dermatol, 1997,36:582-588.
[13] Kagi MK, Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Br J Dermatol, 2001,145:350-351.
[14] Dittmar HC, Pflieger D, Schopf E, et al.UVA1 phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis. Hautarzt, 2001,52:423-427.
[15] Hjerppe M, Hasan T, Saksala I, et al.Narrow-band UVB treatment in atopic dermatitis. Acta Derm Venereol, 2001,81:439-440.
[16] Richter HI, Billmann-Eberwein C, Grewe M, et al. Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol, 1998,38:585-588.
[17] Prinz B, Michelsen S, Pfeiffer C, et al. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol, 1999,40:577-582.
[18] Paller A, Eichenfield LF, Leung DY, et al.A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol,2001,44:S47-S57.
[19] Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol,1998,134:805-809.
[20] Wahn U, Bos JD, Good field M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics, 2002,110:e2.
[21] Hanifin JM, Chan SC, Cheng JB, et al.Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol, 1996,107:51-56.
[22] Chamlin SL, Kao J, Frieden I J, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis:changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol, 2002,47:198-208. |
